Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - erlotinib hydrochloride 109.29mg equivalent to erlotinib 100 mg; erlotinib hydrochloride 109.29mg equivalent to erlotinib 100 mg; erlotinib hydrochloride 109.29mg equivalent to erlotinib 100 mg; erlotinib hydrochloride 109.29mg equivalent to erlotinib 100 mg - film coated tablet - 100 mg - active: erlotinib hydrochloride 109.29mg equivalent to erlotinib 100 mg erlotinib hydrochloride 109.29mg equivalent to erlotinib 100 mg erlotinib hydrochloride 109.29mg equivalent to erlotinib 100 mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose opacode grey s-1-27645 opadry white y-5-7068 sodium laurilsulfate sodium starch glycolate active: erlotinib hydrochloride 109.29mg equivalent to erlotinib 100 mg excipient: hyprolose hypromellose lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose opadry white y-5-7068 sodium laurilsulfate sodium starch glycolate titanium dioxide - · tarceva is indicated for the first-line and maintenance treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. · tarceva is also indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer (nsclc) who have previously received chemotherapy.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - erlotinib hydrochloride, quantity: 163.93 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; magnesium stearate; sodium lauryl sulfate; lactose monohydrate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - non-small cell lung cancer: tarceva is indicated for the first-line treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. tarceva is indicated for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutations who have not progressed on first-line chemotherapy. tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy. pancreatic cancer: tarceva in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - erlotinib hydrochloride, quantity: 109.29 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - non-small cell lung cancer: tarceva is indicated for the first-line treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. tarceva is indicated for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutations who have not progressed on first-line chemotherapy. tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy. pancreatic cancer: tarceva in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - erlotinib hydrochloride, quantity: 27.32 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; sodium lauryl sulfate; sodium starch glycollate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - non-small cell lung cancer: tarceva is indicated for the first-line treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. tarceva is indicated for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutations who have not progressed on first-line chemotherapy. tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy. pancreatic cancer: tarceva in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Singapur - angielski - HSA (Health Sciences Authority)

hetero singapore pte. ltd. - erlotinib hydrochloride eqv erlotinib - tablet, film coated - erlotinib hydrochloride eqv erlotinib 100.000 mg

Izrael - angielski - Ministry of Health

taro international ltd, israel - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 150 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib taro is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib taro is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib taro is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib taro is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Izrael - angielski - Ministry of Health

taro international ltd, israel - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 25 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib taro is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib taro is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib taro is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib taro is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Izrael - angielski - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 150 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib s.k. is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib s.k. is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib s.k. is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib s.k. is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - erlotinib hydrochloride 109.267mg equivalent to erlotinib 100 mg - film coated tablet - 100 mg - active: erlotinib hydrochloride 109.267mg equivalent to erlotinib 100 mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose opadry white y-5-7068 purified water sodium laurilsulfate sodium starch glycolate - non-small cell lung cancer erlotinib is indicated for the first-line and maintenance treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. erlotinib is also indicated for the treatment of patients with locally advanced or metastatic nsclc who have previously received chemotherapy.

Malta - angielski - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - erlotinib hydrochloride - film-coated tablet - erlotinib hydrochloride 100 mg - antineoplastic agents